文献速递浆细胞疾病

达雷妥尤单抗联合伊沙佐米和地塞米松在来那度胺暴露后一线治疗后的患者中的疗效与安全性:2期研究DARIA的最终结果

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
PubMed 文献 · Am J Hematol · 2024-01-31

这项前瞻性2期研究DARIA评估达雷妥尤单抗联合伊沙佐米和地塞米松(Dara-Ixa-dex)用于既往接受过一线含来那度胺方案后来那度胺暴露的复发/难治多发性骨髓瘤患者,共入组50例,总缓解率为64%,中位无进展生存期8.1个月,中位总生存期39.2个月,42%患者发生≥1次3/4级不良事件,最常见为血小板减少。

要点

  • Dara-Ixa-dex在来那度胺暴露的复发/难治多发性骨髓瘤患者中总缓解率为64%。
  • 中位随访23.4个月,中位无进展生存期8.1个月,中位总生存期39.2个月。
  • 42%患者发生≥1次3/4级不良事件,最常见为血小板减少(18%)。

核心结论

  • 对于既往接受过一线含来那度胺方案治疗的复发/难治多发性骨髓瘤患者,二线Dara-Ixa-dex治疗可产生快速缓解,并对骨代谢有有利影响。

研究设计与样本

  • 前瞻性2期研究DARIA,入组50例既往接受过一线含来那度胺方案治疗的复发/难治多发性骨髓瘤患者,中位年龄69岁,男性占56%。

主要发现

  • 32例(64%)患者来那度胺难治,17例(34%)曾接受自体移植。
  • 总缓解率为64%(n=32),其中17例(34%)达到非常好的部分缓解或更好,中位首次缓解时间1.0个月。
  • 中位随访23.4个月,中位无进展生存期8.1个月,中位总生存期39.2个月。
  • 骨代谢标志物在治疗6个月时即出现显著变化。
  • 21例(42%)患者发生≥1次3/4级不良事件,最常见为血小板减少(n=9,18%);14例(28%)患者发生≥1次严重不良事件,最常见为急性肾损伤和肺炎(各n=2);4例患者死于感染。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of lenalidomide in frontline therapy for patients with newly diagnosed multiple myeloma (MM) has increased the number of those who become refractory to lenalidomide at second line. In this context, we assessed the efficacy of daratumumab in combination with ixazomib and dexamethasone (Dara-Ixa-dex) in the prospective phase 2 study DARIA. Eligible patients had relapsed/refractory MM (RRMM) after one prior line with a lenalidomide-based regimen. The primary endpoint was overall response rate (ORR). Secondary endpoints included survival outcomes, safety and changes in biomarkers of bone metabolism. Overall, 50 patients were enrolled (median age 69 years, 56% males). 32 (64%) patients were refractory to lenalidomide, and 17 (34%) had undergone autologous transplant. The ORR was 64% (n = 32); whereas 17 (34%) had a very good partial response or better. The median time to first response was 1.0 month. After a median follow-up of 23.4 months, the median PFS and OS were 8.1 and 39.2 months, respectively. Furthermore, significant changes in markers of bone metabolism became evident as early as at 6 months on treatment. Regarding safety, 21 (42%) patients had ≥1 grade 3/4 adverse event (AE); the most common was thrombocytopenia (n = 9, 18%). 14 (28%) patients had ≥1 serious AE (SAE), the most common being acute kidney injury and pneumonia (n = 2, each). Four patients died due to infections. In conclusion, second-line treatment with Dara-Ixa-dex in patients with RRMM pre-treated with a lenalidomide-based regimen resulted in rapid responses along with a favorable effect on bone metabolism.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA. Am J Hematol. 2024. PMID: 38298023. doi:10.1002/ajh.27206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。